4.47
+0.145(+3.36%)
Currency In USD
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
8
First IPO Date
December 16, 2021
| Name | Title | Pay | Year Born |
| Spyridon Papapetropoulos | Chief Executive Officer, President & Executive Director | 827,683 | 1973 |
| Adrian Hinton | Financial Controller | 199,202 | 1952 |
| Elizabeth Doolin | Senior Vice President of Clinical Development | 205,999 | 1965 |
| Timothy Cunningham | Chief Financial Officer | 254,363 | 1962 |
| Julie Kerner | Senior Vice President of Business Operations | 0 | N/A |
| Mark A. Smith | Chief Medical Officer | 0 | 1955 |
| Rajeev Chandra | Company Secretary | 0 | N/A |
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.